Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment
Portfolio Pulse from
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) announced a positive independent safety review for its ADAPT clinical trial, validating the safety and potential of CELZ-201 for treating chronic lower back pain.
November 13, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Creative Medical Technology Holdings received a positive safety review for its ADAPT clinical trial, which could enhance investor confidence in CELZ-201's potential for treating chronic lower back pain.
The positive safety review from the DSMB is a significant milestone for CELZ's ADAPT trial, indicating that CELZ-201 is safe for further development. This news is likely to boost investor confidence and positively impact CELZ's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100